Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis(412 views) Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Cattedra di Radiologia, Università Federico II, via Pansini 5, 80131 Napoli, Italy
Divisione di Emato-Oncologia, Ospedale Umberto I, ASL SA1, Nocera Inferiore, SA, Italy
Divisione di Ematologia, Ospedale di S. Felice a Cancello, ASL Caserta 1, Italy
Cattedra di Ematologia, Federico II University, via Pansini 5, 80131 Napoli, Italy
References: Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J., Engroff, S.L., Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases (2004) J Oral Maxillofac Surg, 62, pp. 527-53
Marx, R.E., Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic (2003) J Oral Maxillofac Surg, 61, pp. 1115-1118
Ruggiero, S., Gralow, J., Marx, R.E., Hoff, A.O., Schubert, M.M., Huryn, J.M., Toth, B., Valero, V., Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer (2006) J Oncol Pract, 2, pp. 7-14
Fleisch, H., Bisphosphonate: Mechanisms of action (1998) Endocr Rev, 19, pp. 80-100
Ashcroft, A.J., Davies, F.E., Morgan, G.J., Aetiology of bone disease and the role of bisphosphonates in multiple myeloma (2003) Lancet Oncol, 4, pp. 284-292
Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Knight, R.D., Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (1996) N Engl J Med, 334, pp. 488-493
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L.A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Dimopoulos, M.A., Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors (2005) J Clin Oncol, 23, pp. 8580-8587
Durie, B.G.M., Katz, M., Crowley, J., Osteonecrosis of the jaw and bisphosphonates (2005) N Engl J Med, 353, pp. 99-102
Catalano, L., Caparrotti, G., Martorelli, M.C., Califano, C., Esposito, D., Cicoira, L., Graziani, F., Rotoli, B., Bisphosphonates and risk of osteonecrosis of the jaw (2006) Haema, 9, pp. 410-414
Ciu, M.L., Kronauge, J.F., Piwnica-Worms, D., Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-1653
Kostkiewicz, M., Tracz, W., Przewlocki, T., Kawalec, E., Predictive potential of noninvasive methods, inclusive of exercise SPECT Tc99m MIBI imaging, in recognition of high-risk patients with left main coronary artery stenosis (2001) Int J Cardiovasc Imaging, 17, pp. 347-352
Hassan, I.M., Sahweil, A., Costantinides, C., Mahmound, A., Nair, M., Omar, Y.T., Abdel-Dayem, H.M., Uptake and kinetics of tc-99m hexakis 2-methoxyisobutyl isonitrile in benign and malignant lesions in the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Caner, B., Kitapci, M., Aras, T., Erbengi, G., Ugur, O., Bekdik, C., Increased accumulation of 2-methoxyisobutylisonitrile technetium in osteosarcoma and its metastatic lymph nodes (1991) J Nucl Med, 32, pp. 1977-1978
Kitapci, M.T., Tastekin, G., Turgut, M., Caner, B., Kars, A., Barista, I., Bekdik, C., Preoperative localization of parathyroid carcinoma using 99m Tc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C.H., Wang, S.J., Liu, T.J., The use of technetium-99m-methoxyisobutyl isonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Wakasugi, S., Teshima, H., Nakamura, H., Hashizume, T., Maeda, T., Hiraoka, A., Hasegawa, Y., Masaoka, T., Tc-99m MIBI localization in bone marrow: A marker of bone marrow malignancy (1998) Clin Nucl Med, 23, pp. 664-671
Tirovola, E.B., Biassoni, L., Britton, K.E., Kaleva, N., Kouykin, V., Malpas, J.S., The use of Tc-99m MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
Adams, B.K., Fataar, A., Nizami, M.A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Pace, L., Catalano, L., Del Vecchio, S., Di Gennaro, F., De Renzo, A., Sica, G., Califano, C., Salvatore, M., Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow up (2001) Eur J Nucl Med, 28, pp. 304-312
Balleari, E., Villa, G., Garre, S., Ghirlanda, P., Agnese, G., Carletto, M., Clavio, M., Ghio, R., Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease (2001) Haematologica, 86, pp. 78-84
Svaldi, M., Tappa, C., Gebert, U., Bettini, D., Fabris, P., Franzelin, F., Osele, L., Mitterer, M., Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation (2001) Ann Hematol, 80, pp. 393-397
Fonti, R., Del Vecchio, S., Zanetti, A., De Renzo, A., Di Gennaro, F., Catalano, L., Califano, C., Salvatore, M., Bone marrow uptake of 99m Tc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Catalano, L., Pace, L., Califano, C., Pinto, A.M., De Renzo, A., Di Gennaro, F., Del Vecchio, S., Rotoli, B., Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy (1999) Haematologica, 84, pp. 119-124
Jadvar, H., Conti, P.S., Diagnostic utility of FDG-PET in multiple myeloma (2002) Skeletal Radiol, 31, pp. 690-694
Schirrmeister, H., Bommer, M., Buck, A.K., Muller, S., Messer, P., Bunjes, D., Initial results in the assessment of multiple myeloma using FDG-PET (2002) Eur J Nucl Med, 29, pp. 361-366
Durie, G.M., Waxman, A.D., D'Agnolo, A., Williams, C.M., Whole body 18F-FDG-PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Nanni, C., Zamagni, E., Farsad, M., Castellucci, P., Tosi, P., Cangini, D., Salizzzoni, E., Fanti, S., Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results (2006) Eur J Nucl Med Mol Imaging, 33, pp. 525-531
Mileshkin, L., Blum, R., Seymour, J.F., Patrikeos, A., Hicks, R.J., Prince, H.M., A comparison of fluorine-18 fluorodeoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma (2004) Eur J Haematol, 72, pp. 32-37
Shreve, P.D., Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease (1998) Eur J Nucl Med, 25, pp. 259-264
Yamada, S., Kubota, K., Kubota, R., Ido, T., Tamahashi, N., High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue (1995) J Nucl Med, 36, pp. 1301-1306
Strauss, L.G., Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients (1996) Eur J Nucl Med, 23, pp. 1409-1415
Knight, S.B., Delbeke, D., Stewart, J.R., Sandler, M.P., Evaluation of pulmonary lesions with FDG-PET (1996) Chest, 109, pp. 982-988
El-Haddad, G., Zhuang, H., Gupta, N., Alavi, A., Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders (2004) Semin Nucl Med, 34, pp. 313-329
Catalano, L., Andretta, C., Pace, L., Del Vecchio, S., Fonti, R., Pollio, G., Salvatore, B., Rotoli, B., Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy (2004) Haema, 7, pp. 329-334
Talamo, G., Angtuaco, E., Walker, R.C., Dong, L., Miceli, M.H., Zangari, M., Tricot, G., Anaissie, E., Avascular necrosis of femoral and/or humeral heads in multiple myeloma: Results of a prospective study on patients treated with dexamethasone-based regimens and high-dose chemotherapy (2005) J Clin Oncol, 23, pp. 5217-5223
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., Engroff, S. L., Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases (2004) J Oral Maxillofac Surg, 62, pp. 527-53
Marx, R. E., Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic (2003) J Oral Maxillofac Surg, 61, pp. 1115-1118
Ashcroft, A. J., Davies, F. E., Morgan, G. J., Aetiology of bone disease and the role of bisphosphonates in multiple myeloma (2003) Lancet Oncol, 4, pp. 284-292
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Knight, R. D., Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (1996) N Engl J Med, 334, pp. 488-493
Durie, B. G. M., Katz, M., Crowley, J., Osteonecrosis of the jaw and bisphosphonates (2005) N Engl J Med, 353, pp. 99-102
Ciu, M. L., Kronauge, J. F., Piwnica-Worms, D., Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-1653
Hassan, I. M., Sahweil, A., Costantinides, C., Mahmound, A., Nair, M., Omar, Y. T., Abdel-Dayem, H. M., Uptake and kinetics of tc-99m hexakis 2-methoxyisobutyl isonitrile in benign and malignant lesions in the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Kitapci, M. T., Tastekin, G., Turgut, M., Caner, B., Kars, A., Barista, I., Bekdik, C., Preoperative localization of parathyroid carcinoma using 99m Tc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C. H., Wang, S. J., Liu, T. J., The use of technetium-99m-methoxyisobutyl isonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Tirovola, E. B., Biassoni, L., Britton, K. E., Kaleva, N., Kouykin, V., Malpas, J. S., The use of Tc-99m MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
Adams, B. K., Fataar, A., Nizami, M. A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Durie, G. M., Waxman, A. D., D'Agnolo, A., Williams, C. M., Whole body 18F-FDG-PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Shreve, P. D., Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease (1998) Eur J Nucl Med, 25, pp. 259-264
Strauss, L. G., Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients (1996) Eur J Nucl Med, 23, pp. 1409-1415
Knight, S. B., Delbeke, D., Stewart, J. R., Sandler, M. P., Evaluation of pulmonary lesions with FDG-PET (1996) Chest, 109, pp. 982-988
Kapucu, L. O., Meltzer, C. C., Townsend, D. W., Keenan, R. J., Luketich, J. D., Fluorine-18-fluoro-deoxyglucose uptake in pneumonia (1998) J Nucl Med, 39, pp. 1267-1269
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote